ArticleBioengineering (Basel, Switzerland)2026
3D-Printed Poly(Lactic-co-Glycolic Acid) Binder-Based Self-Hardening Calcium Phosphate Bone Scaffolds.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensionally (3D)-printed alpha-tricalcium phosphate (α-TCP) scaffolds, fabricated through a low-temperature hydrothermal dissolution-precipitation process, replicate the structural and compositional features of native bone. Reinforcing hydrothermally processed α-TCP with poly(lactic-co-glycolic acid) (PLGA) as a binder has previously been shown to confer distinct mechanical advantages, supporting its potential as a viable material for bone regenerative scaffolds. Although the hydrothermal processing of α-TCP scaffolds and PLGA-based mechanical reinforcement have each been characterized individually in earlier studies, this work represents the first pre-clinical in vivo assessment of osseoconduction and biocompatibility of 3D-printed, PLGA-reinforced, self-hardening calcium phosphate scaffolds in a large translational animal model. A ceramic ink suitable for extrusion was prepared by combining a 30 wt/vol% poloxamer 407 solution with α-TCP powder at a 0.45 wt/wt ratio (CTRL). A second extrudable ink, consisting of an α-TCP ceramic suspension incorporating a 35 wt/wt% PLGA binder, was formulated at a 0.5 wt/wt ratio (EXP). Cylindrical scaffolds (6 mm × 6 mm) were fabricated at room temperature using a custom-built Direct Ink Write 3D printer, then hydrothermally treated via submersion in water and thermal consolidation at 121 °C. Osteotomies were created in the ilium of adult sheep, with two cylindrical defects (7 mm × 6 mm) per animal, each receiving either a CTRL or EXP scaffold. Animals were euthanized at 3 and 12 weeks post-surgery (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.